Physician profile
Bilal Islam
NPI 1124361431
$6,366.91
in general payments reported to CMS, 2019-2025
30 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 92% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.95 · 2021: $637 · 2022: $1,138 · 2023: $1,878 · 2024: $1,243 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.35 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,249.23 | 2019-2025 | Evenity, Enbrel, Prolia |
| Novartis Pharmaceuticals Corporation | $1,111.18 | 2021-2025 | |
| Ucb, INC. | $1,028.30 | 2021-2025 | Bimzelx, Cimzia |
| Sonex Health, INC. | $852.57 | 2021-2025 | Sx-One Microknife |
| Trice Medical, INC. | $419.27 | 2021-2023 | |
| Janssen Biotech, INC. | $219.16 | 2023-2024 | Tremfya, Stelara |
| Horizon Therapeutics Plc | $175.14 | 2021-2023 | Krystexxa |
| Hydrocision, INC. | $148.36 | 2023-2024 | Tenjet |
| Mallinckrodt Hospital Products INC. | $121.49 | 2021-2023 | Acthar |
| Bioventus LLC | $117.59 | 2022-2025 | Durolane, Xcell |
| Abbvie INC. | $100.96 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $95.81 | 2024-2025 | Iovera, Zilretta |
| Genzyme Corporation | $88.68 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $83.50 | 2024-2025 | Euflexxa |
| Aurinia Pharma U.S., INC. | $76.27 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.08 | 2022-2024 | Ofev |
| Averitas Pharma INC. | $48.07 | 2023 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $46.90 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $40.10 | 2022-2023 | |
| Octapharma USA, INC. | $39.00 | 2022-2023 | Octagam Immune Globulin (Human) |
| Grt US Holding, INC. | $36.99 | 2021 | |
| Organon LLC | $36.52 | 2023-2024 | Hadlima |
| Avanos Medical | $28.02 | 2023 | Coolief* Cooled Radiofrequency |
| Ani Pharmaceuticals, INC. | $24.35 | 2022 | |
| Lundbeck LLC | $21.07 | 2022 | |
| Tonix Medicines, INC. | $20.52 | 2025 | Tonmya |
| Lilly USA, LLC | $19.96 | 2023 | Taltz |
| Emmaus Medical, INC. | $19.89 | 2021 | |
| Genentech USA, INC. | $14.98 | 2023 | Actemra |
| Kaleo, INC. | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Islam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.